메뉴 건너뛰기




Volumn 47, Issue 3, 2012, Pages 227-235

Canadian expert consensus: Optimal treatment of neovascular age-related macular degeneration

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; BETA CAROTENE; BEVACIZUMAB; PEGAPTANIB; PLACEBO; RANIBIZUMAB; STEROID; VERTEPORFIN; ZINC;

EID: 84862298230     PISSN: 00084182     EISSN: 17153360     Source Type: Journal    
DOI: 10.1016/j.jcjo.2012.03.007     Document Type: Article
Times cited : (24)

References (83)
  • 1
    • 0036786670 scopus 로고    scopus 로고
    • Ten-year incidence of agerelated maculopathy and smoking and drinking: The Beaver Dam Eye Study
    • Klein R, Klein BE, Tomany SC, Moss SE. Ten-year incidence of agerelated maculopathy and smoking and drinking: The Beaver Dam Eye Study. Am J Epidemiol. 2002;156:589-98.
    • (2002) Am J Epidemiol , vol.156 , pp. 589-598
    • Klein, R.1    Klein, B.E.2    Tomany, S.C.3    Moss, S.E.4
  • 3
    • 0038708118 scopus 로고    scopus 로고
    • Age-related macular degeneration: Etiology, pathogenesis, and therapeutic strategies
    • DOI 10.1016/S0039-6257(03)00030-4
    • Ambati J, Ambati BK, Yoo SH, et al. Age-related macular degeneration: Etiology, pathogenesis, and therapeutic strategies. Surv Ophthalmol. 2003;48:257-93. (Pubitemid 36553096)
    • (2003) Survey of Ophthalmology , vol.48 , Issue.3 , pp. 257-293
    • Ambati, J.1    Ambati, B.K.2    Yoo, S.H.3    Ianchulev, S.4    Adamis, A.P.5
  • 4
    • 0026681119 scopus 로고
    • Prevalence of age-related maculopathy: The Beaver Dam Eye Study
    • Klein R, Klein BEK, Linton KLP. Prevalence of age-related maculopathy: The Beaver Dam Eye Study. Ophthalmology. 1992;99:933-43.
    • (1992) Ophthalmology , vol.99 , pp. 933-943
    • Klein, R.1    Klein, B.E.K.2    Linton, K.L.P.3
  • 5
    • 0028843796 scopus 로고
    • Prevalence of age-related maculopathy in Australia: The Blue Mountain Eye Study
    • Mitchell P, Smith W, Altebo K, Wang JJ. Prevalence of age-related maculopathy in Australia: The Blue Mountain Eye Study. Ophthalmology. 1995;102:1450-60.
    • (1995) Ophthalmology , vol.102 , pp. 1450-1460
    • Mitchell, P.1    Smith, W.2    Altebo, K.3    Wang, J.J.4
  • 6
    • 0028839002 scopus 로고
    • The prevalence of agerelated maculopathy in the Rotterdam Study
    • Vingerling JR, Diclemans I, Hofman A, et al. The prevalence of agerelated maculopathy in the Rotterdam Study. Ophthalmology. 1995;102: 205-10.
    • (1995) Ophthalmology , vol.102 , pp. 205-210
    • Vingerling, J.R.1    Diclemans, I.2    Hofman, A.3
  • 7
    • 50249172959 scopus 로고    scopus 로고
    • Age-period-cohort effect on the incidence of age-related macular degeneration: The Beaver Dam Eye Study
    • Klein R, Knudtson MD, Lee KE, et al. Age-period-cohort effect on the incidence of age-related macular degeneration: The Beaver Dam Eye Study. Ophthalmology. 2008;115:1460-7.
    • (2008) Ophthalmology , vol.115 , pp. 1460-1467
    • Klein, R.1    Knudtson, M.D.2    Lee, K.E.3
  • 9
    • 0038010714 scopus 로고    scopus 로고
    • Progression of age-related macular degeneration: Association with body mass index, waist circumference, and waist-hip ratio
    • DOI 10.1001/archopht.121.6.785
    • Seddon JM, Cote J, Davis N, Rosner B. Progression of age-related macular degeneration: Association with body mass index, waist circumference, and waist-hip ratio. Arch Ophthalmol. 2003;121:785-92. (Pubitemid 36676214)
    • (2003) Archives of Ophthalmology , vol.121 , Issue.6 , pp. 785-792
    • Seddon, J.M.1    Cote, J.2    Davis, N.3    Rosner, B.4
  • 10
    • 55949093510 scopus 로고    scopus 로고
    • Changes in abdominal obesity and age-related macular degeneration: The Atherosclerosis Risk in Communities Study
    • Peeters A, Magliano DJ, Stevens J, et al. Changes in abdominal obesity and age-related macular degeneration: The Atherosclerosis Risk in Communities Study. Arch Ophthalmol. 2008;126:1554-60.
    • (2008) Arch Ophthalmol , vol.126 , pp. 1554-1560
    • Peeters, A.1    Magliano, D.J.2    Stevens, J.3
  • 13
    • 33747185607 scopus 로고    scopus 로고
    • Associations between intermediate age-related macular degeneration and lutein and zeaxanthin in the Carotenoids in Age-Related Eye Disease Study (CAREDS): Ancillary study of the Women's Health Initiative
    • DOI 10.1001/archopht.124.8.1151
    • Moeller SM, Parekh N, Tinker L, et al. Associations between intermediate age-related macular degeneration and lutein and zeaxanthin in the Carotenoids in Age-related Eye Disease Study (CAREDS): Ancillary study of the Women's Health Initiative. Arch Ophthalmol. 2006;124: 1151-62. (Pubitemid 44232345)
    • (2006) Archives of Ophthalmology , vol.124 , Issue.8 , pp. 1151-1162
    • Moeller, S.M.1    Parekh, N.2    Tinker, L.3    Ritenbaugh, C.4    Blodi, B.5    Wallace, R.B.6    Mares, J.A.7
  • 14
    • 34548650913 scopus 로고    scopus 로고
    • The relationship of dietary carotenoid and vitamin A, E, and C intake with age-related macular degeneration in a case-control study: AREDS Report No. 22
    • Age-Related Eye Disease Study Research Group
    • Age-Related Eye Disease Study Research Group. The relationship of dietary carotenoid and vitamin A, E, and C intake with age-related macular degeneration in a case-control study: AREDS Report No. 22. Arch Ophthalmol. 2007;125:1225-32.
    • (2007) Arch Ophthalmol , vol.125 , pp. 1225-1232
  • 15
    • 45149132510 scopus 로고    scopus 로고
    • Dietary ω-3 fatty acid and fish intake in the primary prevention of age-related macular degeneration: A systematic review and meta-analysis
    • DOI 10.1001/archopht.126.6.826
    • Chong EW, Kreis AJ, Wong TY, et al. Dietary omega-3 fatty acid and fish intake in the primary prevention of age-related macular degeneration: A systematic review and meta-analysis. Arch Ophthalmol. 2008; 126:826-33. (Pubitemid 351831334)
    • (2008) Archives of Ophthalmology , vol.126 , Issue.6 , pp. 826-833
    • Chong, E.W.-T.1    Kreis, A.J.2    Wong, T.Y.3    Simpson, J.A.4    Guymer, R.H.5
  • 16
    • 0034800655 scopus 로고    scopus 로고
    • A randomized, placebo- controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS Report No. 8
    • Age-Related Eye Disease Study Research Group
    • Age-Related Eye Disease Study Research Group. A randomized, placebo- controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS Report No. 8. Arch Ophthalmol. 2001; 119:1417-36.
    • (2001) Arch Ophthalmol , vol.119 , pp. 1417-1436
  • 20
    • 67749120186 scopus 로고    scopus 로고
    • Meta-analysis of the association of the HTRA1 polymorphisms with the risk of age-related macular degeneration
    • Chen W, Xu W, Tao Q, et al. Meta-analysis of the association of the HTRA1 polymorphisms with the risk of age-related macular degeneration. Exp Eye Res. 2009;89:292-300.
    • (2009) Exp Eye Res , vol.89 , pp. 292-300
    • Chen, W.1    Xu, W.2    Tao, Q.3
  • 21
    • 33750300013 scopus 로고    scopus 로고
    • Association between apolipoprotein E polymorphisms and age-related macular degeneration: A HuGE review and meta-analysis
    • DOI 10.1093/aje/kwj279
    • Thakkinstian A, Bowe S, McEvoy M, et al. Association between apolipoprotein E polymorphisms and age-related macular degeneration: A HuGE review and meta-analysis. Am J Epidemiol. 2006;164:813-22. (Pubitemid 44627265)
    • (2006) American Journal of Epidemiology , vol.164 , Issue.9 , pp. 813-822
    • Thakkinstian, A.1    Bowe, S.2    McEvoy, M.3    Smith, W.4    Attia, J.5
  • 22
    • 33748752137 scopus 로고    scopus 로고
    • Systematic review and meta-analysis of the association between complementary factor H Y402H polymorphisms and age-related macular degeneration
    • DOI 10.1093/hmg/ddl220
    • Thakkinstian A, Han P, McEvoy M, et al. Systematic review and metaanalysis of the association between complement factor H Y402H polymorphisms and age-related macular degeneration. Hum Mol Genet. 2006;15:2784-90. (Pubitemid 44400405)
    • (2006) Human Molecular Genetics , vol.15 , Issue.18 , pp. 2784-2790
    • Thakkinstian, A.1    Han, P.2    McEvoy, M.3    Smith, W.4    Hoh, J.5    Magnusson, K.6    Zhang, K.7    Attia, J.8
  • 23
    • 36549016602 scopus 로고    scopus 로고
    • Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab
    • DOI 10.1016/j.ophtha.2007.09.008, PII S0161642007010263
    • Brantley MA Jr, Fang AM, King JM, et al. Association of complement factor H and LOC387715 genotypes with response of exudative agerelated macular degeneration to intravitreal bevacizumab. Ophthalmology. 2007;114:2168-73. (Pubitemid 350181136)
    • (2007) Ophthalmology , vol.114 , Issue.12 , pp. 2168-2173
    • Brantley Jr., M.A.1    Fang, A.M.2    King, J.M.3    Tewari, A.4    Kymes, S.M.5    Shiels, A.6
  • 25
    • 0023224438 scopus 로고
    • Pathophysiology of age-related macular degeneration
    • DOI 10.1016/0039-6257(87)90115-9
    • Young RW. Pathophysiology of age-related macular degeneration. Surv Ophthalmol. 1987;31:291-306. (Pubitemid 17076515)
    • (1987) Survey of Ophthalmology , vol.31 , Issue.5 , pp. 291-306
    • Young, R.W.1
  • 27
    • 39049142223 scopus 로고    scopus 로고
    • Pegaptanib sodium for the treatment of age-related macular degeneration
    • DOI 10.1517/14656566.9.3.499
    • Apte RS. Pegaptanib sodium for the treatment of age-related macular degeneration. Expert Opin Pharmacother. 2008;9:499-508. (Pubitemid 351291794)
    • (2008) Expert Opinion on Pharmacotherapy , vol.9 , Issue.3 , pp. 499-508
    • Apte, R.S.1
  • 28
    • 20044375603 scopus 로고    scopus 로고
    • Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro
    • DOI 10.1007/s10456-004-8272-2
    • Wang Y, Fei D, Vanderlaan M, Song A. Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis. 2004; 7:335-45 (Pubitemid 40767935)
    • (2004) Angiogenesis , vol.7 , Issue.4 , pp. 335-345
    • Wang, Y.1    Fei, D.2    Vanderlaan, M.3    Song, A.4
  • 29
    • 33749632278 scopus 로고    scopus 로고
    • Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration
    • DOI 10.1097/01.iae.0000242842.14624.e7, PII 0000698220061000000002
    • Ferrara N, Damico L, Shams N, et al. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina. 2006; 26:859-70. (Pubitemid 44547437)
    • (2006) Retina , vol.26 , Issue.8 , pp. 859-870
    • Ferrara, N.1    Damico, L.2    Shams, N.3    Lowman, H.4    Kim, R.5
  • 31
    • 52949113486 scopus 로고    scopus 로고
    • Vitreous levels of bevacizumab and vascular endothelial growth factor-A in patients with choroidal neovascularization
    • Zhu Q, Ziemssen F, Henke-Fahle S, et al. Vitreous levels of bevacizumab and vascular endothelial growth factor-A in patients with choroidal neovascularization. Ophthalmology. 2008;115):1750-5.
    • (2008) Ophthalmology , Issue.115 , pp. 1750-1755
    • Zhu, Q.1    Ziemssen, F.2    Henke-Fahle, S.3
  • 32
    • 36549039554 scopus 로고    scopus 로고
    • Pharmacokinetics of Intravitreal Ranibizumab (Lucentis)
    • DOI 10.1016/j.ophtha.2007.09.012, PII S0161642007010305
    • Bakri SJ, Snyder MR, Reid JM, et al. Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology. 2007;114:2179-82. (Pubitemid 350181137)
    • (2007) Ophthalmology , vol.114 , Issue.12 , pp. 2179-2182
    • Bakri, S.J.1    Snyder, M.R.2    Reid, J.M.3    Pulido, J.S.4    Ezzat, M.K.5    Singh, R.J.6
  • 33
    • 51649109046 scopus 로고    scopus 로고
    • Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans
    • Krohne TU, Eter N, Holz FG, Meyer CH. Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans. Am J Ophthalmol. 2008;146:508-12.
    • (2008) Am J Ophthalmol , vol.146 , pp. 508-512
    • Krohne, T.U.1    Eter, N.2    Holz, F.G.3    Meyer, C.H.4
  • 35
    • 36749003833 scopus 로고    scopus 로고
    • Pharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbits
    • DOI 10.1097/IAE.0b013e318134eecd, PII 0000698220071100000018
    • Gaudreault J, Fei D, Beyer JC, et al. Pharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbits. Retina. 2007;27:1260-6. (Pubitemid 350211535)
    • (2007) Retina , vol.27 , Issue.9 , pp. 1260-1266
    • Gaudreault, J.1    Fei, D.2    Beyer, J.C.3    Ryan, A.4    Rangell, L.5    Shiu, V.6    Damico, L.A.7
  • 37
    • 57949094834 scopus 로고    scopus 로고
    • Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study
    • ANCHOR Study Group
    • Brown DM, Michels M, Kaiser PK, et al., ANCHOR Study Group. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology. 2009;116:57-65.
    • (2009) Ophthalmology , vol.116 , pp. 57-65
    • Brown, D.M.1    Michels, M.2    Kaiser, P.K.3
  • 38
    • 38349172455 scopus 로고    scopus 로고
    • Randomized, doublemasked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1
    • Regillo CD, Brown DM, Abraham P, et al. Randomized, doublemasked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol. 2008; 145:239-48.
    • (2008) Am J Ophthalmol , vol.145 , pp. 239-248
    • Regillo, C.D.1    Brown, D.M.2    Abraham, P.3
  • 40
    • 69249222585 scopus 로고    scopus 로고
    • A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration
    • Boyer DS, Heier JS, Brown DM, et al. A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology. 2009;116:1731-9.
    • (2009) Ophthalmology , vol.116 , pp. 1731-1739
    • Boyer, D.S.1    Heier, J.S.2    Brown, D.M.3
  • 41
    • 57849120440 scopus 로고    scopus 로고
    • Ranibizumab in patients with subfoveal choroidal neovascularization secondary to agerelated macular degeneration: Interim results from the Sustain Trial
    • SUSTAIN Study Group. E-abstract 273
    • Meyer CH, Eter N, Holz FG, SUSTAIN Study Group. Ranibizumab in patients with subfoveal choroidal neovascularization secondary to agerelated macular degeneration: Interim results from the Sustain Trial. Invest Ophthalmol Vis Sci. 2008;49:E-abstract 273.
    • (2008) Invest Ophthalmol Vis Sci , vol.49
    • Meyer, C.H.1    Eter, N.2    Holz, F.G.3
  • 42
    • 33947403618 scopus 로고    scopus 로고
    • An optical coherence tomography- guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration
    • Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography- guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol. 2007;143:566-83.
    • (2007) Am J Ophthalmol , vol.143 , pp. 566-583
    • Fung, A.E.1    Lalwani, G.A.2    Rosenfeld, P.J.3
  • 46
    • 80053354753 scopus 로고    scopus 로고
    • Verteporfin PDT and ranibizumab combination therapy for symptomatic macular polypoidal choroidal vasculopathy (PCV): EVEREST results
    • The EVEREST study group
    • Lai TY, The EVEREST study group. Verteporfin PDT and ranibizumab combination therapy for symptomatic macular polypoidal choroidal vasculopathy (PCV): EVEREST results. Invest Ophthalmol Vis Sci. 2010;51(suppl):S2228.
    • (2010) Invest Ophthalmol Vis Sci , vol.51 , Issue.SUPPL.
    • Lai, T.Y.1
  • 47
    • 56949108327 scopus 로고    scopus 로고
    • A systematic review on the effect of bevacizumab in exudative age-related macular degeneration
    • Schouten JS, La Heij EC, Webers CA, et al. A systematic review on the effect of bevacizumab in exudative age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2009;247:1-11.
    • (2009) Graefes Arch Clin Exp Ophthalmol , vol.247 , pp. 1-11
    • Schouten, J.S.1    La Heij, E.C.2    Webers, C.A.3
  • 48
    • 67649996349 scopus 로고    scopus 로고
    • Off-label use of bevacizumab for the treatment of age-related macular degeneration: What is the evidence?
    • Ziemssen F, Grisanti S, Bartz-Schmidt KU, SpitzerMS. Off-label use of bevacizumab for the treatment of age-related macular degeneration: What is the evidence? Drugs Aging. 2009;26:295-320.
    • (2009) Drugs Aging , vol.26 , pp. 295-320
    • Ziemssen, F.1    Grisanti, S.2    Bartz-Schmidt, K.U.3    Spitzer, M.S.4
  • 49
    • 77951272899 scopus 로고    scopus 로고
    • Intravitreal bevacizumab (Avastin) vs. ranibizumab (Lucentis) for the treatment of age-related macular degeneration: A systematic review
    • Schmucker C, Ehlken C, Hansen LL, et al. Intravitreal bevacizumab (Avastin) vs. ranibizumab (Lucentis) for the treatment of age-related macular degeneration: A systematic review. Curr Opin Ophthalmol. 2010;21:218-26.
    • (2010) Curr Opin Ophthalmol , vol.21 , pp. 218-226
    • Schmucker, C.1    Ehlken, C.2    Hansen, L.L.3
  • 50
    • 79956218863 scopus 로고    scopus 로고
    • Ranibizumab and bevacizumab for neovascular age-related macular degeneration
    • CATT Research Group
    • CATT Research Group. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364:1897-908.
    • (2011) N Engl J Med. , vol.364 , pp. 1897-1908
  • 51
    • 14744267295 scopus 로고    scopus 로고
    • Impact of lesion size on photodynamic therapy with verteporfin of predominantly classic lesions in age related macular degeneration
    • DOI 10.1136/bjo.2004.050997
    • Arias L, Pujol O, Berniell J, et al. Impact of lesion size on photodynamic therapy with verteporfin of predominantly classic lesions in age-related macular degeneration. Br J Ophthalmol. 2005;89:312-5. (Pubitemid 40327615)
    • (2005) British Journal of Ophthalmology , vol.89 , Issue.3 , pp. 312-315
    • Arias, L.1    Pujol, O.2    Berniell, J.3    Rubio, M.4    Roca, G.5    Castillo, L.6    Acebes, E.7
  • 52
    • 14944378549 scopus 로고    scopus 로고
    • Guidelines for using verteporfin (Visudyne) in photodynamic therapy for choroidal neovascularization due to age-related macular degeneration and other causes: Update
    • Verteporfin Roundtable Participants
    • Verteporfin Roundtable Participants. Guidelines for using verteporfin (Visudyne) in photodynamic therapy for choroidal neovascularization due to age-related macular degeneration and other causes: Update. Retina. 2005;25:119-34.
    • (2005) Retina , vol.25 , pp. 119-134
  • 53
    • 34248174811 scopus 로고    scopus 로고
    • Use of optical coherence tomography, fluorescein angiography and indocyanine green angiography in a screening clinic for wet age-related macular degeneration
    • DOI 10.1136/bjo.2006.108043
    • Talks J, Koshy Z, Chatzinikolas K. Use of optical coherence tomography, fluorescein angiography and indocyanine green angiography in a screening clinic for wet age-related macular degeneration. Br J Ophthalmol. 2007;91:600-1. (Pubitemid 46716524)
    • (2007) British Journal of Ophthalmology , vol.91 , Issue.5 , pp. 600-601
    • Talks, J.1    Koshy, Z.2    Chatzinikolas, K.3
  • 54
    • 70549098650 scopus 로고    scopus 로고
    • Optical coherence tomography in neovascular age related macular degeneration compared to fluorescein angiography and visual acuity
    • Henschel A, Spital G, Lommatzsch A, Pauleikhoff D. Optical coherence tomography in neovascular age related macular degeneration compared to fluorescein angiography and visual acuity. Eur J Ophthalmol. 2009; 19:831-5.
    • (2009) Eur J Ophthalmol , vol.19 , pp. 831-835
    • Henschel, A.1    Spital, G.2    Lommatzsch, A.3    Pauleikhoff, D.4
  • 55
    • 65549113426 scopus 로고    scopus 로고
    • Safety and efficacy of intravitreal anti-VEGF injections for age-related macular degeneration
    • Jeganathan VS, Verma N. Safety and efficacy of intravitreal anti-VEGF injections for age-related macular degeneration. Curr Opin Ophthalmol. 2009;20:223-5.
    • (2009) Curr Opin Ophthalmol , vol.20 , pp. 223-225
    • Jeganathan, V.S.1    Verma, N.2
  • 57
    • 74549137478 scopus 로고    scopus 로고
    • Ranibizumab (Lucentis) in neovascular age-related macular degeneration: Evidence from clinical trials
    • Mitchell P, Korobelnik JF, Lanzetta P, et al. Ranibizumab (Lucentis) in neovascular age-related macular degeneration: Evidence from clinical trials. Br J Ophthalmol. 2010;94:2-13.
    • (2010) Br J Ophthalmol , vol.94 , pp. 2-13
    • Mitchell, P.1    Korobelnik, J.F.2    Lanzetta, P.3
  • 58
    • 77953299956 scopus 로고    scopus 로고
    • Identifying systemic safety signals following intravitreal bevacizumab: Systematic review of the literature and the Canadian Adverse Drug Reaction Database
    • Micieli JA, Micieli A, Smith AF. Identifying systemic safety signals following intravitreal bevacizumab: Systematic review of the literature and the Canadian Adverse Drug Reaction Database. Can J Ophthalmol. 2010;45:231-8.
    • (2010) Can J Ophthalmol , vol.45 , pp. 231-238
    • Micieli, J.A.1    Micieli, A.2    Smith, A.F.3
  • 59
    • 84899774968 scopus 로고    scopus 로고
    • CATT: Lucentis-Avastin Trial. Accessed October 27, 2010
    • CATT: Lucentis-Avastin Trial. Manual of Procedures. Available online: www.med.upenn.edu/cpob/studies/documents/CATTManualof ProceduresMay2010-000.pdf. Accessed October 27, 2010.
    • Manual of Procedures
  • 60
    • 77953358874 scopus 로고    scopus 로고
    • High-molecular-weight aggregates in repackaged bevacizumab
    • Kahook MY, Liu L, Ruzycki P, et al. High-molecular-weight aggregates in repackaged bevacizumab. Retina. 2010;30:887-92.
    • (2010) Retina , vol.30 , pp. 887-892
    • Kahook, M.Y.1    Liu, L.2    Ruzycki, P.3
  • 61
    • 64849085452 scopus 로고    scopus 로고
    • Characteristics of severe intraocular inflammation following intravitreal injection of bevacizumab (Avastin)
    • Georgopoulos M, Polak K, Prager F, et al. Characteristics of severe intraocular inflammation following intravitreal injection of bevacizumab (Avastin). Br J Ophthalmol. 2009;93:457-62.
    • (2009) Br J Ophthalmol , vol.93 , pp. 457-462
    • Georgopoulos, M.1    Polak, K.2    Prager, F.3
  • 62
    • 33750296920 scopus 로고    scopus 로고
    • The International Intravitreal Bevacizumab Safety Survey: Using the internet to assess drug safety worldwide
    • DOI 10.1136/bjo.2006.099598
    • Fung AE, Rosenfeld PJ, Reichel E. The International Intravitreal Bevacizumab Safety Survey: Using the internet to assess drug safety worldwide. Br J Ophthalmol. 2006;90:1344-9. (Pubitemid 44702055)
    • (2006) British Journal of Ophthalmology , vol.90 , Issue.11 , pp. 1344-1349
    • Fung, A.E.1    Rosenfeld, P.J.2    Reichel, E.3
  • 64
    • 77953300103 scopus 로고    scopus 로고
    • Incidence and characteristics of acute intraocular inflammation after intravitreal injection of bevacizumab: A retrospective cohort study
    • Johnson D, Hollands H, Hollands S, Sharma S. Incidence and characteristics of acute intraocular inflammation after intravitreal injection of bevacizumab: A retrospective cohort study. Can J Ophthalmol. 2010;45:239-42.
    • (2010) Can J Ophthalmol , vol.45 , pp. 239-242
    • Johnson, D.1    Hollands, H.2    Hollands, S.3    Sharma, S.4
  • 65
    • 77958001574 scopus 로고    scopus 로고
    • Risks of mortality,myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration
    • CurtisLH,HammillBG,SchulmanKA,CousinsSW.Risks of mortality,myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. Arch Ophthalmol. 2010;128:1273-9.
    • (2010) Arch Ophthalmol , vol.128 , pp. 1273-1279
    • Curtis, L.H.1    Hammill, B.G.2    Schulman, K.A.3    Cousins, S.W.4
  • 67
    • 77958001574 scopus 로고    scopus 로고
    • Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration
    • Curtis LH, Hammill BG, Schulman KA, Cousins SW. Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. Arch Ophthalmol. 2010;128:1273-9.
    • (2010) Arch Ophthalmol , vol.128 , pp. 1273-1279
    • Curtis, L.H.1    Hammill, B.G.2    Schulman, K.A.3    Cousins, S.W.4
  • 70
    • 38149099226 scopus 로고    scopus 로고
    • Burden of illness of neovascular age-related macular degeneration in Canada
    • Cruess A, Zlateva G, Xu X, Rochon S. Burden of illness of neovascular age-related macular degeneration in Canada. Can J Ophthalmol. 2007; 42:836-43.
    • (2007) Can J Ophthalmol , vol.42 , pp. 836-843
    • Cruess, A.1    Zlateva, G.2    Xu, X.3    Rochon, S.4
  • 71
    • 77953310762 scopus 로고    scopus 로고
    • Pharmacologic management of neovascular age-related macular degeneration: Systematic review of economic evidence and primary economic evaluation
    • Hodge W, Brown A, Kymes S, et al. Pharmacologic management of neovascular age-related macular degeneration: Systematic review of economic evidence and primary economic evaluation. Can J Ophthalmol. 2010;45:223-30.
    • (2010) Can J Ophthalmol , vol.45 , pp. 223-230
    • Hodge, W.1    Brown, A.2    Kymes, S.3
  • 72
    • 0026575912 scopus 로고
    • How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations
    • Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ. 1992;146:473-81.
    • (1992) CMAJ , vol.146 , pp. 473-481
    • Laupacis, A.1    Feeny, D.2    Detsky, A.S.3    Tugwell, P.X.4
  • 74
    • 1242342156 scopus 로고    scopus 로고
    • Health care economic analyses
    • Brown GC, BrownMM,Sharma S, et al. Health care economic analyses. Retina. 2004;24:139-46.
    • (2004) Retina , vol.24 , pp. 139-146
    • Brown, G.C.1    Brownmmsharma, S.2
  • 76
    • 33947160622 scopus 로고    scopus 로고
    • Ophthalmology human resource projections: Are we heading for a crisis in the next 15 years?
    • DOI 10.1139/I06-115
    • Bellan L, Buske L. Ophthalmology human resource projections: Are we heading for a crisis in the next 15 years? Can J Ophthalmol. 2007;42:34-8. (Pubitemid 46408891)
    • (2007) Canadian Journal of Ophthalmology , vol.42 , Issue.1 , pp. 34-38
    • Bellan, L.1    Buske, L.2
  • 77
    • 70349449765 scopus 로고    scopus 로고
    • The treatment of wet AMD in Canada: Access to therapy (policy review)
    • Cruess A, Maberley D, Wong D, Chen J. The treatment of wet AMD in Canada: access to therapy (policy review). Can J Ophthalmol. 2009;44: 548-56.
    • (2009) Can J Ophthalmol , vol.44 , pp. 548-556
    • Cruess, A.1    Maberley, D.2    Wong, D.3    Chen, J.4
  • 78
    • 84899783898 scopus 로고    scopus 로고
    • Accessed September 6, 2010
    • The Facts on British Columbia's Wet AMD Program. Available online: www.gov.bc.ca/fortherecord/wetamd/wt-healthcare.html?src-/healthcare/ wt-healthcare.html. Accessed September 6, 2010.
    • The Facts on British Columbia's Wet AMD Program
  • 79
    • 43749096100 scopus 로고    scopus 로고
    • Neovascular age-related macular degeneration: Potential therapies
    • DOI 10.2165/00003495-200868080-00002
    • Chappelow AV, Kaiser PK. Neovascular age-related macular degeneration: Potential therapies. Drugs. 2008;68:1029-36. (Pubitemid 351693673)
    • (2008) Drugs , vol.68 , Issue.8 , pp. 1029-1036
    • Chappelow, A.V.1    Kaiser, P.K.2
  • 80
    • 78449283380 scopus 로고    scopus 로고
    • Current and emerging therapies for the treatment of age-related macular degeneration
    • Emerson MV, Lauer AK. Current and emerging therapies for the treatment of age-related macular degeneration. Clin Ophthalmol. 2008;2: 377-88.
    • (2008) Clin Ophthalmol , vol.2 , pp. 377-388
    • Emerson, M.V.1    Lauer, A.K.2
  • 81
    • 70349330817 scopus 로고    scopus 로고
    • VEGF trap-eye for the treatment of neovascular age-related macular degeneration
    • Dixon JA, Oliver SC, Olson JL, Mandava N. VEGF trap-eye for the treatment of neovascular age-related macular degeneration. Expert Opin Investig Drugs. 2009;18:1573-80.
    • (2009) Expert Opin Investig Drugs , vol.18 , pp. 1573-1580
    • Dixon, J.A.1    Oliver, S.C.2    Olson, J.L.3    Mandava, N.4
  • 82
    • 70350757650 scopus 로고    scopus 로고
    • A Phase i study of intravitreal vascular endothelial growth factor trap-eye in patients with neovascular age-related macular degeneration
    • Nguyen QD, Shah SM, Browning DJ, et al. A Phase I study of intravitreal vascular endothelial growth factor trap-eye in patients with neovascular age-related macular degeneration. Ophthalmology. 2009;116: 2141-8.
    • (2009) Ophthalmology , vol.116 , pp. 2141-2148
    • Nguyen, Q.D.1    Shah, S.M.2    Browning, D.J.3
  • 83
    • 84899775941 scopus 로고    scopus 로고
    • VEGF trap-eye noninferior to ranibizumab in two phase 3 trials
    • Accessed January 12, 2010
    • VEGF trap-eye noninferior to ranibizumab in two phase 3 trials. Retina Today. 2010. Available online: www.advancedocularcare.bmctoday.net/retinatoday/ 2010/12/article.asp?f-vegf-trap-eye-noninferior-toranibizumab- in-two-phase-3-trials. Accessed January 12, 2010.
    • (2010) Retina Today


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.